SMARTOX Deploys Over 50 INBS Intelligent Fingerprinting Drug Screening Readers, Facilitating 7,000 Tests as Company Pursues FDA Clearance for U.S. Market Expansion

Intelligent Bio Solutions (INBS) announced progress in the U.S. forensic drug screening market via its partnership with SMARTOX, deploying over 50 fingerprint drug screening readers and conducting 7,000 tests, including 1,500 in 2024. INBS is actively pursuing FDA clearance for its opiate test system for codeine, aiming for broader U.S. market expansion in 2025, while hedge fund activity shows mixed sentiment with some increasing and others decreasing positions in Q1 2025.

Analysis

Intelligent Bio Solutions Inc. (INBS) is demonstrating tangible progress in the U.S. forensic drug screening market through its strategic partnership with SMARTOX, evidenced by the deployment of over 50 Intelligent Fingerprinting Drug Screening Readers and the completion of more than 7,000 tests, with a notable acceleration of over 1,500 tests conducted in 2024 alone. This adoption signals growing demand for INBS's rapid, non-invasive drug screening technology, which reportedly enhances efficiency, user dignity, and reduces operational complexities. A critical upcoming catalyst for INBS is the pursuit of FDA clearance for its opiate test system for codeine, which the company anticipates will facilitate expansion into broader U.S. markets, including workplace drug testing, by 2025. While the technology's benefits are clear, potential investors should note the inherent regulatory risks associated with FDA approval timelines and outcomes, the current reliance on the SMARTOX partnership for U.S. market penetration, and the general uncertainties highlighted in the company's forward-looking statements. Institutional sentiment, as of Q1 2025, appears mixed; while six firms, including significant new positions by Alyeska Investment Group (613,892 shares) and Altium Capital Management (149,252 shares), added to their holdings, seven institutions decreased their positions, with Two Sigma Securities and Ground Swell Capital notably exiting completely.

Key Decisions for Investors

• Investors should closely monitor INBS's progress towards FDA clearance for its opiate test system, as this is a key determinant for broader U.S. market access and significant future growth potential.
• The continued success and potential expansion of the SMARTOX partnership warrants careful observation, alongside any strategic initiatives by INBS to diversify its market channels or secure additional partnerships to mitigate concentration risk.
• Considering the company's current stage of U.S. market entry heavily contingent on regulatory approval, an investment in INBS carries a speculative profile, though the demonstrated demand for its technology and recent institutional interest from firms like Alyeska Investment Group could indicate upside if key milestones are achieved.